0
     

Report Added
Report already added
Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 17, 5, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, and Preclinical stages comprises 1, and 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Warts - Overview
Warts - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Beijing Kangle Guardian Biotechnology Co Ltd
Chengdu Institute of Biological Products Co Ltd
Cutanea Life Sciences Inc
Cytovation AS
Douglas Pharmaceuticals Ltd
Etna Biotech Srl
Feramda Ltd
G&E Herbal Biotechnology Co., Ltd.
Genetic Immunity Inc
Guangzhou Cape Biological Technology Co Ltd
Hefei Ruichengsheng Biotechnology Co Ltd
KinoPharma Inc
Laboratories Ojer Pharma SL
Maruho Co Ltd
Merck & Co Inc
Nielsen Biosciences Inc
Novan Inc
Orgenesis Inc
Peritech Pharma
Phio Pharmaceuticals Corp
Shanghai Bovax Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
Veloce BioPharma LLC
Verrica Pharmaceuticals Inc
Xiamen Innovax Biotech Co Ltd
Warts - Drug Profiles
(lopinavir + ritonavir) - Drug Profile
Product Description
Mechanism Of Action
Albicin - Drug Profile
Product Description
Mechanism Of Action
History of Events
AS-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cantharidin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Condyloma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
Product Description
Mechanism Of Action
chloroquine phosphate - Drug Profile
Product Description
Mechanism Of Action
CyPep-1 - Drug Profile
Product Description
Mechanism Of Action
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
human papillomavirus [serotypes 6, 11] (bivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus vaccine (tetravalent) - Drug Profile
Product Description
Mechanism Of Action
History of Events
HupaDerm - Drug Profile
Product Description
Mechanism Of Action
History of Events
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
History of Events
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
pefcalcitol - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-210 - Drug Profile
Product Description
Mechanism Of Action
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
History of Events
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
Samcyprone - Drug Profile
Product Description
Mechanism Of Action
History of Events
SB-206 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SB-207 - Drug Profile
Product Description
Mechanism Of Action
SCT-1000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Human Papillomavirus Infections - Drug Profile
Product Description
Mechanism Of Action
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VBP-245 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-103 - Drug Profile
Product Description
Mechanism Of Action
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Jan 19, 2021: Verrica Pharmaceuticals presents positive data from clinical studies evaluating the safety and efficacy of VP-102 in molluscum and external genital warts at the 2021 Winter Clinical Dermatology Conference
Nov 10, 2020: Verrica Pharmaceuticals announces positive topline results in Phase 2 clinical study of VP-102 in patients with external genital warts (CARE-1)
Oct 24, 2019: Aclaris Therapeutics A-101 45% topical solution meets primary and all secondary efficacy endpoints in second successful pivotal phase 3 clinical trial for the treatment of common warts (THWART-1)
Oct 18, 2019: Novan further expands its proprietary nitric oxide platform
Oct 18, 2019: Verrica Pharmaceuticals announces presentation of positive data from clinical trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
Sep 16, 2019: Aclaris Therapeutics A-101 45% Topical Solution meets primary and all secondary efficacy endpoints in pivotal phase 3 trial for the treatment of common warts (THWART-2)
Jul 24, 2019: Novan’s drug substance demonstrates inhibition of HPV-18 virus production
Jun 27, 2019: Verrica Pharmaceuticals enrolls first patient in Phase 2 trial of VP-102 for the treatment of external genital warts
Jun 26, 2019: Verrica Pharmaceuticals achieves positive topline results in phase 2 clinical study of VP-102 in [atients with common warts
Mar 18, 2019: Cytovation initiates clinical development programme with CyPep-1, a first-in-class lytic agent for tumor immunotherapy
Feb 19, 2019: Aclaris Therapeutics to present scientific posters at the 77th Annual Meeting of the American Academy of Dermatology
Nov 01, 2018: Novan Publication Supports Women's Health Business Unit Initiative and Nitric Oxide's Potential Against HPV-Associated Diseases
Sep 24, 2018: Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts
Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts
May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Warts, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Warts - Pipeline by Aclaris Therapeutics Inc, 2022
Warts - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Warts - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Warts - Pipeline by Cutanea Life Sciences Inc, 2022
Warts - Pipeline by Cytovation AS, 2022
Warts - Pipeline by Douglas Pharmaceuticals Ltd, 2022
Warts - Pipeline by Etna Biotech Srl, 2022
Warts - Pipeline by Feramda Ltd, 2022
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022
Warts - Pipeline by Genetic Immunity Inc, 2022
Warts - Pipeline by Guangzhou Cape Biological Technology Co Ltd, 2022
Warts - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, 2022
Warts - Pipeline by KinoPharma Inc, 2022
Warts - Pipeline by Laboratories Ojer Pharma SL, 2022
Warts - Pipeline by Maruho Co Ltd, 2022
Warts - Pipeline by Merck & Co Inc, 2022
Warts - Pipeline by Nielsen Biosciences Inc, 2022
Warts - Pipeline by Novan Inc, 2022
Warts - Pipeline by Orgenesis Inc, 2022
Warts - Pipeline by Peritech Pharma, 2022
Warts - Pipeline by Phio Pharmaceuticals Corp, 2022
Warts - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Warts - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Warts - Pipeline by SinoCelltech Group Ltd, 2022
Warts - Pipeline by Veloce BioPharma LLC, 2022
Warts - Pipeline by Verrica Pharmaceuticals Inc, 2022
Warts - Pipeline by Xiamen Innovax Biotech Co Ltd, 2022
Warts - Dormant Projects, 2022
Warts - Dormant Projects, 2022 (Contd..1)
Warts - Discontinued Products, 2022

List of Figures
Number of Products under Development for Warts, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F